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Abstract
Background:  A critical component of disease progression in rheumatoid arthritis (RA) involves
neovascularization associated with pannus formation. 2-methoxyestradiol (2ME2) is a naturally occurring
molecule with no known physiologic function, although at pharmacologic concentrations it has antiproliferative
and antiangiogenic activities. We investigated the impact of orally administered 2ME2 on the initiation and
development of proliferative synovitis using the anti-collagen monoclonal antibodies (CAIA) model.
Methods: Severe polyarticular arthritis was induced in Balb/c female mice by administration of 2 mg of a
monoclonal antibody cocktail intravenously into the tail vein of mice. Twenty-four hours following monoclonal
antibody administration, mice were injected with 25 μg of LPS (E. coli strain 0111:B4) via the intraperitoneal route.
Treatment with 2ME2 (100, 75, 50, 25, 10, 1 mg/kg, p.o., daily), or vehicle control began 24 hrs following LPS
challenge and continued to day 21. Hind limbs were harvested, sectioned and evaluated for DMARD activity and
general histopathology by histomorphometric analysis and immunohistochemistry (vWF staining). In a separate
study, different dosing regimens of 2ME2 (100 mg/kg; q.d. vs q.w. vs q.w. × 2) were evaluated. The effect of
treatment with 2ME2 on gene expression of inflammatory cytokines and angiogenic growth factors in the joint
space was evaluated 5 and 14 days after the induction of arthritis.
Results: Mice treated with 2ME2 beginning 24 hours post anti-collagen monoclonal antibody injection, showed
a dose-dependent inhibition in mean arthritic scores. At study termination (day 21), blinded histomorphometric
assessments of sectioned hind limbs demonstrated decreases in synovial inflammation, articular cartilage
degradation, pannus formation, osteoclast activity and bone resorption. At the maximal efficacious dosing regimen
(100 mg/kg/day), administration of 2ME2 resulted in total inhibition of the study parameters and prevented
neovascularization into the joint. Examination of gene expression on dissected hind limbs from mice treated for
5 or 14 days with 2ME2 showed inhibition of inflammatory cytokine message for IL-1β, TNF-α, IL-6 and IL-17, as
well as the angiogenic cytokines, VEGF and FGF-2.
Conclusion: These data demonstrate that in the CAIA mouse model of RA, 2ME2 has disease modifying activity
that is at least partially attributable to the inhibition of neovascular development. Further, the data suggests new
mechanistic points of intervention for 2ME2 in RA, specifically inhibition of inflammatory mediators and osteoclast
activity.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease that is characterized by progressive joint damage. The
pathology of RA is complex and mediated by several
mechanisms. Early stages of disease progression are
defined by capillary formation, hyperplasia of the syno-
vial membrane, influx of leukocytes and inflammatory
cells, and hypertrophic synoviocytes. Established RA
exhibits cellular infiltration, pannus formation, cartilage
degradation, bone erosion and extensive angiogenesis
restricted to the synovium [1,2].
Improved understanding of the molecular mechanisms
supporting the pathogenesis of rheumatoid arthritis has
revealed new targets for therapeutic intervention. One
such novel target for disease modulation is rheumatoid
arthritis-associated angiogenesis [3,4]. Specifically, in the
context of RA, angiogenesis plays a critical role in perpet-
uating inflammatory and immune responses, as well as
supporting pannus growth and development.
2-Methoxyestradiol (2ME2) is an endogenous, naturally-
occurring metabolite of estradiol with a low affinity for
the estrogen receptor (0.05%). It has antiproliferative,
antiangiogenic and proapoptotic activity [5,6]. Mechanis-
tically, 2ME2 binds to the colchicine binding site of tubu-
lin causing microtubule depolymerization and the down-
regulation of transcription factors, hypoxia inducible fac-
tor 1-alpha (HIF1-α), NF-κB, and Stat-3 [7-10]. 2ME2
inhibits tumor-associated angiogenesis and malignant
progression in multiple tumor models in the absence of
dose-limiting toxicities. Phase 1 & 2 clinical trials in
oncology have been conducted with an oral formulation
of 2ME2 (Panzem® NCD) and manageable changes in
liver function tests and hypophosphatemia have been
described in some patients.
The antiarthritic activity of 2ME2 in preclinical models of
RA has been previously described [11-13]. In two of these
studies the potential impact of 2ME2 on angiogenesis was
directly assessed and conflicting data was generated.
2ME2 failed to block synovial angiogenesis in sections
stained with laminin in a rat adjuvant-induced arthritis
model. In contrast, 2ME2 was shown to block articular
angiogenesis in a rat collagen-induced arthritis model as
measured by vWF staining and decreased synovial gene
expression of vascular endothelial growth factor and
fibroblast growth factor.
In the present study, we determined the impact of 2ME2
in a mouse CAIA model. While special emphasis was
placed on ascertaining the relationship between 2ME2-
induced antiangiogenic and antiarthritic activity, novel
information was also obtained concerning the effects of
2ME2 on additional indicators of disease attenuation. The
results show that 2ME2 has disease-modifying activity
that is at least partly attributable to the inhibition of neo-
vasculature development. In addition, 2ME2 impacts
additional mechanisms involved in the progression of
joint disease, specifically inhibition of inflammation and
bone resorption.
Methods
Animals and Therapeutic Agents
Specific pathogen free 5 to 7 week old Balb/C female mice
were purchased from the Jackson Laboratory (Bar Harbor,
ME) and housed in a barrier facility. In conducting the
research in this report the investigators adhered to the
Principles of Laboratory Animal Care (NIH Publication No.
85-23). 2ME2 in a NanoCrystal®  colloidal dispersion
(NCD) was manufactured by Elan Drug Delivery (King of
Prussia, PA). Control diluent used in these studies com-
prised the NCD without 2ME2. In conducting the research
in this report, the investigators adhered to the Guide for
Laboratory Animals and Care of the Institute of Labora-
tory Animal Resources, National Academy of Sciences,
National Research Council.
Induction of CAIA by Anti-Collagen Monoclonal 
Antibodies and LPS
CAIA was induced by the intravenous injection of mono-
clonal antibodies to CII (Arthrogen-CIA, Chemicon Inter-
national, Inc., Temcula, CA), according to the
manufacturers procedure. Arthrogen-CIA is an arthritis-
inducing mixture of four monoclonal antibodies to anti-
CII resuspended in sterile Dulbecco's PBS. All four mono-
clonal antibodies in this mixture recognize the conserved
epitopes (CB11) shared by various species of CII and
cross-react with homologous and heterologous CII. Three
of these four monoclonal antibodies (F10-21, A2-10, and
D8-6) recognize epitopes clustered within an 84 amino
acid residue fragment. LyC2, mof CB11, and the fourth
monoclonal antibody (D1-2G) react with LyC1. Arthritis
is mediated in this model by immune complex mediated
complement activation [14]. Two mg of Arthrogen-CIA
per mouse were injected intravenously into the tail vein of
mice. Twenty-four hours following monoclonal antibody
administration, mice were injected with 25 μg of LPS (E.
coli strain 0111:B4) via the intraperitoneal route. Treat-
ment with 2ME2 (100, 75, 50, 25, 10, 1 mg/kg, p.o.,
daily), or vehicle control (began 24 hrs following LPS
challenge and continued to day 21. In a separate study,
different dosing regimens of 2ME2 (100 mg/kg; q.d. vs
q.w. vs q.w. × 2) were evaluated. The extent of disease was
scored in a blinded fashion by visual observation using
the following scale: 0 – no signs of involvement, 1 – red-
ness, red spots on paw, 2 – partial swelling, difficulties
with stretching paw; 3 – swelling, no loading on paw; 4 –
maximally swollen paw, no loading. The clinical arthritis
score is the sum of arthritic scores from 4 footpads. Maxi-BMC Musculoskeletal Disorders 2009, 10:46 http://www.biomedcentral.com/1471-2474/10/46
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mal arthritic score is 16 for each mouse. At necropsy, both
right and left hind paws were collected, preserved in 10%
buffered formalin, stored at 4°C and processed for his-
topathology, histomorphometric analyses and immuno-
histochemistry (Skeletech, Inc. Bothell, WA).
Qualitative Histopathology
Paws were decalcified with 5% formic acid, dehydrated
through a series of ascending ethanol solutions and
embedded in paraffin. Saggital sections, through the mid-
dle of the hind paw, were obtained using a rotary micro-
tome (Model RM 2165, Leica Microsystems Inc.,
Bannockburn, IL). Sections of 4 μm thickness were
stained with toluidine blue and further developed for tar-
trate-resistant acid phosphatase reactivity. Alternatively,
sections were stained for von Willebrand factor (vWf)
expression to determine vascularity. All histopathology
scoring was performed blinded. The area of evaluation
included the talus-navicular joint through the navicular to
the second metatarsal joint. The scoring criteria were as
follows:
Cell Infiltration Score
Grade 1: Normal; Grade 2: Mild, subsynovial cell fibrosis
with mild cellular infiltrate consisting primarily of mono-
nuclear type cellular infiltrate. Grade 3: Moderate, subsyn-
ovial cell fibrosis and mononuclear type cellular infiltrate.
Grade 4: Marked, periarticular inflammatory infiltrate,
periarticular fibrosis and marginal osteophyte formation.
Pannus Severity Score
Grade 1: Normal; Grade 2: Mild, vascularized connective
tissue at the margins of the joint; Grade 3: Moderate, vas-
cularized connective tissue involving up to 50% of the car-
tilage surface; Grade 4: Marked, vascularized connective
tissue covers more than 50% of the cartilage surface.
Cartilage Lesion Severity Score
Grade 1: Normal; Grade 2: Mild loss of matrix staining
and articular cartilage surface damage; Grade 3: Moderate,
clear reduction of the matrix staining and damage to the
articular cartilage. Grade 4: Marked, ankylosis of the joint
with marked loss of the articular cartilage.
Bone Resorption Severity Score
Grade 1: Normal; Grade 2: Mild appearance of bone
resorption at the margin of the bone. Grade 3: Moderate,
bone resorption involving subchondral bone with intact
articular cartilage and bone interface: Grade 4: Marked,
bone resorption involving extensive subchondral and
marginal area with loss of intact articular cartilage and
bone interface.
Quantitative Histomorphometric Analysis
Disease manifestation in the stained sections was quanti-
fied using Osteomeasure software (Osteometer, Atlanta,
GA). The following five parameters were either obtained
directly by tracing and dotting or were calculated: percent-
age of damaged articular surface, percentage of articular
area without proteoglycan staining, thickness of articular
cartilage, thickness of articular cartilage without prote-
oglycan staining and osteoclast number per marrow area.
Cytokine Analysis
Hind limbs, including the ankle joint were removed and
snap frozen in liquid nitrogen. TRIzol, (1 mL; Invitrogen,
Carlsbad, CA) was added to the joint, which was subse-
quently homogenized using a polytron homogenizer
(PT1300D, Kinematica AG, Newark, NJ). Homogenate
was transferred to Eppendorf tubes and spun for 10 min
at 1000 rpm. Supernatants were removed and 200 μl of
chloroform was added to 1 mL of supernatant, which was
then spun for 15 min at 12,000 rpm at 4°C. The aqueous
layer was removed and an equal volume of ethanol was
added for RNA extraction. Extraction of total RNA from
mouse hind limbs was performed using the RNeasy mini
kit (Qiagen, Germantown, MD) as per the manufacturer's
instructions. Quantity of RNA and its purity was measured
by reading absorbance at 260 and 280 nm. One μg of total
RNA was used to prepare cDNA using Taqman Reverse
Transcription reagents (Applied Biosystems, Warrington,
England) as per the manufacturer's instructions. Real time
PCR was performed using the ABI7300 Sequence Detec-
tion systems (Applied Biosystems, Warrington, England).
Pre-designed Taqman Gene Expression Assays (Applied
Biosystems) for IL-6 (assay ID Mm00446190_m1), IL-1β
(assay ID Mm00434228_m1), TNF-α (assay ID
Mm00443258_m1), VEGF (assay ID Mm00437304_m1)
FGF-2 (assay ID Mm00433287_m1), and IL-17 (assay ID
Mm00433287_m1) were used to detect gene expression.
Taqman Eukaryotic 18s rRNA was used as an endogenous
control. The PCR conditions were as follows: an initial
incubation at 50°C for 2 min, then a denaturation at
95°C for 10 min followed by 50 cycles of 95°C for 15 sec
and 60°C for 1 min. The relative quantitation of gene
expression was performed using the comparative CT
(DDCT) method.
Statistical Analysis
Statistical analyses were determined by non-parametric
Wilcoxon test for comparisons of arthritic scores and real
time PCR quantitation. The significance of the arthritic
score was determined on study day 10 post-arthritis
induction. For histomorphometric analysis, data on study
day 21 from right and left hind paws from individual ani-
mals were combined for the purpose of analysis. Group
summaries were presented as mean and standard devia-
tion. Qualitative histopathology parameters were statisti-BMC Musculoskeletal Disorders 2009, 10:46 http://www.biomedcentral.com/1471-2474/10/46
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cally analyzed using a non-parametric Wilcoxon test.
Qualitative histomorphometry parameters were analyzed
using an unpaired t-test. Each group was individually
compared to all other treated groups. The statistical anal-
yses were conducted using SAS statistical analysis software
(SAS Institute, Cary, NC).
Results
2ME2 Treatment Dose-Dependently Reduces Arthritic 
Score in a Mouse Model of Rheumatoid Arthritis
To investigate the antiarthritic effect of 2ME2, the collagen
antibody-induced arthritis model in mice was employed.
In this model, arthritis is induced in Balb/c mice by the
combination of a sub-arthrogenic dose of four mono-
clonal antibodies to type II collagen followed by lipopol-
ysaccharide (LPS). Oral administration with control
diluent or 2ME2 (1, 10, and 100 mg/kg, q.d.) was initi-
ated 2 h following LPS administration and continued for
21 consecutive days. Mice were assessed on study days 2,
4, 8, and 10 for disease progression by assessing clinical
severity of paw swelling, erythema, and loss of passive use
from all four footpads. Robust joint inflammation devel-
oped in animals receiving vehicle control, with a maximal
mean clinical score of 14.2 reached by study day 10 (Fig-
ure 1 and 2). Mice treated by daily oral gavage with 2ME2
had significantly reduced clinical scores on study day 10
and the extent of joint involvement was dose-dependent.
As compared to control-treated mice, 2ME2 doses of 1,
10, and 100 mg/kg/day inhibited arthritic score by 26, 54,
and 83%, respectively (Figure 1, p < 0.05 for all three
doses when compared to vehicle control). In an addi-
tional study, the antiarthritic activity of 2ME2 was further
evaluated by increasing the doses assessed to 100, 75, 50,
25 10 mg/kg, p.o. daily. Under these experimental condi-
tions, the maximum antiarthritic effect was achieved with
oral administration of 75 or 100 mg/kg daily (data not
shown).
To evaluate whether daily dosing was required to elicit
antiarthritic activity, a dose regimen evaluation was per-
formed in the same model. Robust joint inflammation
developed in animals receiving vehicle control, with a
Daily Gavage with 2ME2 Decreases Arthritic Score in an Antibody-Induced Model of Rheumatoid Arthritis Figure 1
Daily Gavage with 2ME2 Decreases Arthritic Score in an Antibody-Induced Model of Rheumatoid Arthritis. 
Female Balb/c mice (5–7 weeks of age) were injected i.v. with a monoclonal antibody cocktail against type II collagen (2 mg/
mouse). Twenty-four hours later, mice were treated i.p. with 25 μg LPS (E. coli strain 0111:B4). Subsequent to LPS administra-
tion, cohorts of mice (n = 15/group) began treatment by daily oral gavage with either vehicle control or 2ME2 at 1, 10, or 100 
mg/kg for 21 consecutive days. Mice were assessed on study days 2, 4, 8, and 10 for clinical severity of disease progression by 
observing paw swelling, erythema, and a loss of passive use. Maximum arthritic score is 16 for each mouse. Asterisks indicate 
groups statistically different from vehicle control on study day 10 (p < 0.05). This experiment is representative of 4 experi-
ments.
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maximal mean clinical score of 11.1 reached by study day
10 (Figure 3). Daily dosing of 2ME2 (100 mg/kg) resulted
in 68% inhibition of arthritis in the joints. Reducing
administration of 2ME2 (100 mg/kg) to twice a week or
once weekly regimen resulted in a decrease in antiarthritic
activity (45 and 37% inhibition, respectively). While all
three dosing regimens resulted in statistically significant
differences when compared to vehicle control treated ani-
mals (P < 0.05), daily dosing with 2ME2 generated antiar-
thritic activity that was statistically different from both
weekly and twice weekly treatment. The weekly regimens
were not statistically different from each other.
Treatment with 2ME2 Inhibits Parameters of Disease 
Progression
To determine the impact of 2ME2 treatment on joint
inflammation and destruction, mice were necropsied on
study day 21 and both right and left hind paws were proc-
essed for histopathology and histomorphometric analyses
(Skeletech, Bothell, WA). The tissue sections were blinded
and graded for severity of cellular infiltration, pannus for-
mation, cartilage lesions and bone resorption using a 1–4
scaling metric. At study termination (day 21), the articular
joints from mice treated with vehicle control showed a
pronounced cellular infiltration, pannus, and erosions in
both cartilage and bone (Figure 4). Under identical exper-
imental conditions, mice treated with 2ME2 demon-
strated a dose-dependent attenuation of leukocyte
infiltration, pannus severity, and destruction of cartilage
bone (Figure 4). As compared to vehicle control-treated
mice, the lack of development in all four parameters of
disease progression following 2ME2 treatment at 10 or
100 mg/kg/day was statistically significant. Notably, treat-
ment with 100 mg/kg/day of 2ME2 was nearly 100%
effective in the inhibition of the inflammatory response
and tissue destructive processes in this model.
When the joint sections were evaluated histologically,
periarticular inflammatory infiltrates, fibrosis and osteo-
phyte formation were readily apparent in mouse tissue
following treatment with vehicle control (Figure 5A).
These pathological phenomenon were dose-dependently
inhibited with 2ME2 treatment. At the highest dose of
2ME2 (100 mg/kg/day) infiltration of inflammatory cells
and osteophyte formation were completely blocked (Fig-
ure 5B). In fact, histology from joints treated with this
Abrogation of the Articular Inflammatory Response in Mice Treated with 2ME2 Figure 2
Abrogation of the Articular Inflammatory Response in Mice Treated with 2ME2. On study day 8, right and left hind 
paws were fixed in formalin, sectioned and stained by H&E. Intense inflammation is evident in the joints of mice receiving treat-
ment with control diluent (A). In contrast, treatment of mice with 100 mg/kg/day of 2ME2 has essentially abrogated the inflam-
matory response (B). Magnification = 10×.
B ABMC Musculoskeletal Disorders 2009, 10:46 http://www.biomedcentral.com/1471-2474/10/46
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dose of 2ME2 was indistinguishable from normal non-
arthritic joints.
In addition to scoring the qualitative parameters
described above, quantitative histomorphometric analy-
sis was performed on the sectioned paws. Assessment of
total osteoclast number per marrow area revealed
increased osteoclastic activity in the joints of mice treated
with vehicle control (34 osteoclasts in the vehicle control
group). A dose-dependent decrease in osteoclasts was evi-
dent in animals treated with 2ME2 (Table 1). In fact, treat-
ment with 100 mg/kg/day of 2ME2 resulted in complete
ablation of osteoclast numbers (zero osteoclasts present).
In TRAP stained sections, loss of articular proteoglycan
and induction of osteoclast activity were readily apparent
in mouse tissue from animals treated with vehicle control
(Figure 5C). In contrast, treatment of mice with 100 mg/
kg/day 2ME2 resulted in abrogation of these histopatho-
logic changes and the appearance of normal joint archi-
tecture (Figure 5D). Treatment with this dose of 2ME2 was
able to salvage potentially damaged articular cartilage
resulting in a reduction in damaged articular cartilage sur-
face and areas of articular cartilage that lack proteoglycan
staining and an increase in thickness of total articular car-
tilage area to normal appearance.
2ME2 Completely Blocks Neovascularization Associated 
with CAIA
2ME2 is well characterized as an antiangiogenic agent in a
number of oncology models. Angiogenesis is known to
play a prominent role in pannus formation in rheumatoid
arthritis. To assess a potential mechanism by which 2ME2
may be exerting its antiarthritic activity, we stained joint
samples for von Willebrand factor (vWF), a marker used
to visualize angiogenesis. Hind limbs from animals
treated with the control diluent or 2ME2 (100 mg/kg/day)
were collected on Day 21, fixed in 10% buffered formalin,
sectioned and stained. While a significant amount of vWF
staining was present in sections from mice treated with
vehicle control (Figure 6A), there was complete abroga-
tion of angiogenesis as measured by vWF staining in sec-
tions from mice treated with 100 mg/kg/day of 2ME2
(Figure 6B).
Maximum Antiarthritic Activity is Observed With Daily Dosing with 2ME2 Figure 3
Maximum Antiarthritic Activity is Observed With Daily Dosing with 2ME2. Female Balb/c mice (5–7 weeks of age) 
were injected i.v. with a monoclonal antibody cocktail against type II collagen (2 mg/mouse). Twenty-four hours later, mice 
were treated i.p. with 25 μg LPS (E. coli strain 0111:B4). Subsequent to LPS administration, cohorts of mice (n = 10/group) 
began treatment by daily oral gavage with either vehicle control or 2ME2 at 100 mg/kg for 10 consecutive days. Additional 
cohorts of mice were treated weekly or twice a week with 2ME2 at 100 mg/kg. Mice were assessed on study days 2, 4, 8, and 
10 for clinical severity of disease progression by observing paw swelling, erythema, and a loss of passive use. Maximum arthritic 
score is 16 for each mouse. Asterisks indicate groups statistically different from vehicle control on study day 10 (p < 0.05).
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2ME2 Blocks Gene Expression of Angiogenic and 
Inflammatory Cytokines in Arthritic Limbs
To further investigate the mechanism of the antiang-
iogenic and anti-inflammatory effects of 2ME2 in this ani-
mal model of rheumatoid arthritis, gene expression of
angiogenic factors and inflammatory molecules in
afflicted joints were evaluated. Hind limbs from mice
treated with either vehicle control or 2ME2 were harvested
and homogenized on study days 5 and 14. mRNA was
extracted from these samples and gene expression for the
pro-angiogenic molecules, vascular endothelial growth
factor (VEGF) and basic fibroblast growth factor (FGF-2),
and gene expression for the pro-inflammatory molecules
TNFα, IL-1β, IL-6 and IL-17 were established at both time
points. Mice treated daily with 2ME2, demonstrated sup-
pressed expression levels of angiogenic (VEGF, FGF-2)
and inflammatory (TNFα, IL-1β, IL-6 and IL-17) mole-
cules on study day 5 (Figure 7). Expression levels
remained suppressed when assessed on study day 14 (Fig-
ure 8).
Discussion
Data presented in this manuscript demonstrates that the
administration of 2ME2 in a mouse collagen antibody-
induced model of rheumatoid arthritis leads to marked
inhibition of arthritic disease. We show that 2ME2 modi-
fies disease progression through (i) inhibition of articular
angiogenesis, (ii) attenuation of inflammatory cell infil-
tration into the synovial compartment, (iii) abrogation of
soft tissue and bone lesions, and (iv) arrest of pannus
development. In addition, a number of cytokines impor-
tant for recruitment of inflammatory cells and bone
remodeling were modulated in the diseased joint area by
daily oral administration of 2ME2. These data, taken
Effect of 2ME2 on Qualitative Histopathology Parameters Figure 4
Effect of 2ME2 on Qualitative Histopathology Parameters. Five mice from each group were necropsied on study day 
21. At necropsy, both right and left hind paws were collected, preserved in 10% buffered formalin, and processed for histopa-
thology and histomorphometric analyses. Qualitative histopathology scoring was performed using acid phosphatase/toluidine 
blue stained sections on blinded samples. The area of interest included the area from the talus-navicular joint to the navicular 
to the second metatarsal joint. Asterisks indicate groups statistically different from vehicle control (p < 0.05).
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Inhibition of Disease Progression by Treatment with 2ME2 Figure 5
Inhibition of Disease Progression by Treatment with 2ME2. On study day 21, periarticular inflammatory infiltrates 
(arrow heads), fibrosis (asterisks) and osteophyte (arrows) are readily apparent in mouse tissue following induction with mon-
oclonal antibodies to type II collagen and treatment with vehicle control (A). In contrast, treatment of mice with 100 mg/kg/day 
2ME2 resulted in abrogation of these histopathologic changes and the appearance of normal architecture (B). Loss of articular 
proteoglycan (arrows) and induction of osteoclast activity (asterisk) were observed in tissue from mice treated with vehicle 
control (C). In contrast, treatment of mice with 100 mg/kg/day 2ME2 resulted in abrogation of these histopathologic changes 
and the appearance of normal joint architecture (D). Magnification = 60×.
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Table 1: Effect of 2ME2 on Quantitative Histomorphometry Parameters
Treatment Group Total Osteoclast 
Numbers
Articular cartilage area 
without proteoglycan 
staining (%)
Damaged articular 
cartilage surface (%)
Thickness of total 
articular cartilage area 
(μM)
Vehicle Control 33.9 17.23 47.3 26.06
2ME2 100 mg/kg 0 0.18* 0* 32.64*
2ME2 10 mg/kg 5.7* 6.71 27.9 27.34
2ME2 1 mg/kg 21.9* 11.21 37.0 27.5
Quantitative histomorphometry was performed using Ostemeasure software interfaced with a Nikon Eclipse E400 light/epiflourescent microscope 
and video system. Histomorphometric measurements of the articular area and surface were performed using Safranin O stained slides and 
osteoclast number was counted using acid phosphatase/toluidine blue stained slides using blinded samples. The area of interest included the area 
from the talus-navicular joint to the navicular to the second metatarsal joint. Results are presented as mean determinations from 10 observations 
(*p < 0.05 compared to vehicle control).
2ME2 Inhibits Angiogenesis in the Antibody-Induced Model of Rheumatoid Arthritis Figure 6
2ME2 Inhibits Angiogenesis in the Antibody-Induced Model of Rheumatoid Arthritis. On study day 21, right and 
left hind paws were fixed in formalin, sectioned and stained for vWF, a marker of angiogenesis and endothelial cell prolifera-
tion. Abundant staining for vWF factor was evident in sections from mice treated with vehicle control (A). In contrast, treat-
ment of mice with 100 mg/kg/day of 2ME2 completely blocked vWF staining (B). Magnification = 10×.
ABBMC Musculoskeletal Disorders 2009, 10:46 http://www.biomedcentral.com/1471-2474/10/46
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together, support a potential role for 2ME2 as a disease
modifying agent for rheumatoid arthritis. The mecha-
nism(s) by which 2ME2 exerts its preclinical antiarthritic
activity likely involves multiple pathophysiological proc-
esses.
New blood vessel formation is one of the many processes
required for the pathogenesis of proliferative synovitis, of
which RA is the prototype [15-18]. Studies have demon-
strated that multiple proangiogenic molecules are present
in the rheumatoid synovium in animal models and in the
joint fluid in human RA, including vascular endothelial
growth factor (VEGF) [19-23] and basic fibroblast growth
factor (FGF-2) [24,25]. In preclinical animal models,
pharmacological inhibition of angiogenesis with specific
inhibitors to VEGF and FGF-2 results in attenuation of
joint swelling and destruction typically associated with RA
disease progression [26-29]. Further, a variety of other
angiogenesis inhibitors (thalidomide, taxol, angiostatin,
endostatin positively impact preclinical models of RA [30-
35] suggesting a critical contribution of these factors to
disease pathology. However, to date these promising pre-
clinical results have not been translated to positive clinical
outcomes.
The antiangiogenic activity of 2ME2 has been demon-
strated in vivo in a number of systems including the cor-
neal micropocket and chick chorioallantoic assays [5]. In
addition, administration of 2ME2 leads to a reduction of
tumor vasculature in a variety of tumor models [5,6]. In
vitro  studies have demonstrated that 2ME2 inhibits
endothelial cell proliferation, migration and tube forma-
Effect of 2ME2 on Expression of Angiogenic and Inflammatory Cytokines Figure 7
Effect of 2ME2 on Expression of Angiogenic and Inflammatory Cytokines. Total RNA from mouse hind limbs on 
study day 5 was isolated and gene expression of inflammatory (IL-6, IL-1b, TNF-a, IL-17) and angiogenic cytokines (VEGF, FGF-
2) was assessed. Expression of all molecules evaluated were down-modulated upon treatment with 2ME2.BMC Musculoskeletal Disorders 2009, 10:46 http://www.biomedcentral.com/1471-2474/10/46
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tion. 2ME2 treatment also inhibits microvessel branching
from rat aortic rings growing in three-dimensional colla-
gen gels. We assessed the impact of 2ME2 treatment on
angiogenesis in a murine collagen-induced model of RA.
Oral treatment with 2ME2 (100 mg/kg/day) completely
abrogated staining of articular regions for vWF as com-
pared to control-treated mice. In addition, oral treatment
with 2ME2 (100 mg/kg/day) inhibited the expression of
both VEGF and FGF-2 in the joint space as compared to
control-treated mice. Collectively, these data suggest that
2ME2 inhibits the neovascular response elicited in this
collagen antibody-induced model of RA and suggests that
at least a part of the antiarthritic mechanism involves the
down modulation of the proangiogenic cytokines, VEGF
and FGF-2.
In addition to neovascularization, another early event in
preclinical models of RA is the mobilization and infiltra-
tion of leukocytes into the synovium and articular fluid as
well as intense inflammation. Following treatment with
2ME2 in this model, we observed a marked attenuation of
synovial leukocyte infiltrate histologically. To further
explore this 2ME2-mediated effect, we looked at the
expression of inflammatory cytokines in resected joints.
The inflammatory cytokines, TNF-α, IL-1β, IL-6 and IL-17
are all regulatory factors responsible for the initiation, per-
petuation and destructive capacity of the rheumatoid
arthritis synovium and all four have been implicated in
recruitment of inflammatory cells to the joint [36]. In
mice treated daily with 2ME2, the expression levels of
TNF-α, IL-1β, IL-6 and IL-17 were suppressed early (study
day 5) and remained suppressed when assessed on study
day 14. The impact of 2ME2 treatment on cytokine expres-
sion and its relationship to the antiarthritic activity con-
tinues to be investigated.
The progressive destruction of the structural components
of the joints involving the articular cartilage, the bone at
the joint margins, as well as periarticular and subchondral
bone, is another hallmark in the progression of RA. The
impact of 2ME2 treatment on cartilage and bone destruc-
tion in this murine CAIA model was assessed by histomor-
phology and radiography. Oral treatment with 2ME2
demonstrated a dose-dependent inhibition of bone
Effect of 2ME2 on Expression of Angiogenic and Inflammatory Cytokines Figure 8
Effect of 2ME2 on Expression of Angiogenic and Inflammatory Cytokines. Total RNA from mouse hind limbs on 
study day 14 was isolated and gene expression of inflammatory (IL-6, IL-1b, TNF-a, IL-17) and angiogenic cytokines (VEGF, 
FGF-2) was assessed. Expression of all molecules evaluated were down-modulated upon treatment with 2ME2.
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resorption, and ablated osteoclast activity and number
when compared to control-treated mice as determined by
TRAP staining. Parallel analyses also indicated the sparing
of articular cartilage damage as measured by proteoglycan
loss and maintenance of total cartilage thickness. As indi-
cated above, treatment with 2ME2 in this model is associ-
ated with an inhibition in the expression of TNF-α, IL-1β,
IL-6 and IL-17, VEGF, and FGF-2 in resected joints. These
cytokines are abundant in inflamed synovium and pro-
duce marked disturbances of bone and cartilage remode-
ling leading to destruction of the extracellular matrices of
these tissues [37,38]. In addition, it is documented that,
FGF-2 directly accelerates osteoclast maturation and pro-
motes bone resorption [39]. Hence, the impact on the
expression of these inflammatory and angiogenesis fac-
tors by 2ME2 is likely be at least partially responsible for
the striking attenuation and almost complete inhibition
of tissue destruction observed in the mouse collagen anti-
body-induced model of arthritis.
Finally, we demonstrate that the development of pannus
or granulation tissue that grows over and invades articular
cartilage is also positively influenced by 2ME2. In this
model, oral treatment with 2ME2 demonstrated a dose-
dependent inhibition of pannus formation. This activity
may occur as a result of the inhibitory effects of 2ME2 on
angiogenesis and inflammation as noted above. However,
it is not understood if additional described mechanisms
of 2ME2 action (induction of apoptosis and inhibition of
proliferation) may also be relevant for the observed
antiarthritic activity [5,6]. 2ME2 targets actively proliferat-
ing cells and is not cytotoxic to quiescent cells. The anti-
proliferative activities of 2ME2 have been attributed to
several mechanisms, including effects on superoxide dis-
mutase enzymatic activity and microtubule structures [7-
9]. Disruption of the microtubule cytoskeleton by 2ME2
results in the inhibition of expression and activity of the
transcription factor, HIF-1α[10]. This results in a reduc-
tion in expression of the HIF-1α responsive gene, VEGF.
Interestingly, in the context of RA, cytoplasmic and
nuclear overexpression of HIF-1α is described in the syn-
ovial lining in rheumatoid arthritis patients offering
another potential target for antiarthritic activity of 2ME2.
Conclusion
2ME2 exerts pre-clinical antiarthritic activity in a mouse
collagen antibody induced model of RA through multiple
disease modifying actions: (1) inhibition of articular ang-
iogenesis, (2) attenuation of inflammatory cell infiltra-
tion into the synovial compartment, (3) abrogation of
soft tissue and bone lesions, and (4) arrest of pannus
development. Whether these effects occur as the conse-
quence of 2ME2 impacting a single pathway or multiple
pathways continues to be investigated. Taken together, the
disease-modifying activity of 2ME2 following oral admin-
istration in the absence of overt toxicity make 2ME2 an
attractive and suitable therapeutic agent for treating rheu-
matoid arthritis and warrants clinical evaluation.
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